Press Releases Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 21/01/2025 GMT			5-day change	1st Jan Change
264.99 ^USD	+7.60%		+2.60%	+12.61%

01-13	Alnylam Pharmaceuticals, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 09:45 AM
01-12	Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2025	CI

Press Releases

Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals	01-12	BU
City Therapeutics Appoints Andy Orth as Chief Executive Officer	01-08	AQ
Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference	01-06	BU
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference	11-27	BU
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy	11-25	BU
Alnylam Announces Interim Phase 1 Data of Nucresiran Showing Rapid Knockdown of TTR that is sustained at Six Months Following a Single Dose	11-18	AQ
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose	11-17	BU
Alnylam to Webcast Presentations at Upcoming November Investor Conferences	11-04	BU
Alnylam Pharmaceuticals to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024	31/10/24	AQ
Alnylam Pharmaceuticals : Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity Form 8 K	31/10/24	PU
Alnylam: Q3 Earnings Snapshot	31/10/24	AQ
Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity	31/10/24	BU
Alnylam Pharmaceuticals : Q3 2024 Presentation ›	31/10/24	PU
Alnylam Pharmaceuticals : Q3 2024 GAAP/Non-GAAP Reconciliation ›	31/10/24	PU
Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024	30/10/24	BU
Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results	17/10/24	BU
Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy	16/10/24	BU
Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy	09/10/24	BU
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024	29/09/24	BU
Alnylam to Webcast TTR Investor Day	26/09/24	BU
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress	02/09/24	AQ
Del. Judge Connolly Says Preambles Are Limiting, Cites Alice In Wonderland, And Invites The Federal Circuit To Weigh In	02/09/24	AQ
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress	30/08/24	BU
Alnylam to Webcast Presentations at Upcoming September Investor Conferences	28/08/24	BU
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024	08/08/24	AQ

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Pharmaceuticals

Press Releases

Filters